.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,225,196

« Back to Dashboard

Details for Patent: 5,225,196

Title: Bioadhesive compositions and methods of treatment therewith
Abstract:A controlled release treatment composition method of use are disclosed. The composition includes a bioadhesive and an effective amount of a treating agent. The bioadhesive is a water-swellable, but water-insoluble, fibrous, cross-linked carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkenyl polyether.
Inventor(s): Robinson; Joseph R. (Madison, WI)
Assignee: Columbia Laboratories, Inc. (Hollywood, FL)
Filing Date:Jan 07, 1991
Application Number:07/638,184
Claims:1. A controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of an ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble, particulate cross-linked carboxyl-functional polymer said polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid and mixtures thereof having particles sized so that visual impairment is substantially minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linked agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzend, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight.

2. A controlled release ophthalmic treatment composition as recited in claim 1 wherein said bioadhesive and said treating agent are intimately admixed substantially uniform.

3. A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 90 percent of said polymer repeating units contain at least one carboxyl functionality.

4. A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl funtionality.

5. A controlled release ophthalmic treatment composition as recited in claim 1 wherein said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.

6. A controlled release ophthalmic treatment composition as recited in claim 1 wherein said carboxyl functionality is provided by polymerized acrylic acid.

7. A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl functionality provided by acrylic acid, and said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.

8. A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 3,4-dihydroxy-1,5-hexadiene.

9. A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is divinyl benzene.

10. A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 1,5-dimethyl-1,5-hexadiene.

11. A controlled release ophthalmic treatment composition as recited in any one of claims 1-10, inclusive, wherein said ophthalmic treating agent constitutes an anti-inflammatory agent.

12. A controlled release ophthalmic treatment composition as recited in claim 11 wherein said anti-inflammatory agent is fluorometholone.

13. A method of controlled release ophthalmic treatment comprising the steps of:

(A) providing a controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble , particulate cross-linked carboxyl-functional polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid, and mixtures thereof having particles sized so that visual impairment is minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linking agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzene, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight percent.

14. A method as recited in claim 13 wherein said bioadhesive and said treating agent are intimately admixed substantially uniformly.

15. A method as recited in claim 13 wherein at least about 90 percent of said polymer repeating units contain at least one carboxyl functionality.

16. A method as recited in claim 13 wherein said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.

17. A method as recited in claim 13 wherein said carboxyl functionality is provided by polymerized acrylic acid.

18. A method as recited in claim 13 wherein said anti-inflammatory agent is fluorometholone.

19. A method as recited in claim 18 wherein said anti-inflammatory agent is fluorometholone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc